Obadiah J. Plante

Obadiah J. Plante


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
CDCailin Deal
Cailin Deal
ACAndrea Carfi
Andrea Carfi
OPObadiah J. Plante
Obadiah J. Plante
Monoclonal antibodies are the fastest growing therapeutic class in medicine today. They hold great promise for a myriad of indications, including cancer, allergy, autoimmune and infectious diseases. However, the wide accessibility of these therapeutics is hindered by manufacturing and purification challenges that result in high costs and long lead times. Efforts are being made to find alternative ways to produce and deliver antibodies in more expedient and cost-effective platforms. The field of mRNA has made significant progress in the last ten years and has emerged as a highly attractive means of encoding and producing any protein of interest in vivo. Through the natural role of mRNA as a transient carrier of genetic information for translation into proteins, in vivo expression of mRNA-encoded antibodies offer many advantages over recombinantly produced antibodies. In this review, we examine both preclinical and clinical studies that demonstrate the feasibility of mRNA-encoded antibodies and discuss the remaining challenges ahead.

1 November 2023 in Cell Reports Medicine
Verified
Journal Article
Open access
CDCailin Deal
Cailin Deal
ARAngelene F. Richards
Angelene F. Richards
TYTracy Yeung
Tracy Yeung
MMMax J. Maron
Max J. Maron
ZWZiqiu Wang
Ziqiu Wang
OPObadiah J. Plante
Obadiah J. Plante
Colonization of the gut and airways by pathogenic bacteria can lead to local tissue destruction and life-threatening systemic infections, especially in immunologically compromised individuals. Here, we describe an mRNA-based platform enabling delivery of pathogen-specific immunoglobulin A (IgA) monoclonal antibodies into mucosal secretions. The platform consists of synthetic mRNA encoding IgA heavy, light, and joining (J) chains, packaged in lipid nanoparticles (LNPs) that express glycosylated, dimeric IgA with functional activity in vitro and in vivo. Importantly, mRNA-derived IgA had a significantly greater serum half-life and a more native glycosylation profile in mice than did a recombinantly produced IgA. Expression of an mRNA encoded Salmonella-specific IgA in mice resulted in intestinal localization and limited Peyer's patch invasion. The same mRNA-LNP technology was used to express a Pseudomonas-specific IgA that protected from a lung challenge. Leveraging the mRNA antibody technology as a means to intercept bacterial pathogens at mucosal surfaces opens up avenues for prophylactic and therapeutic interventions.

13 August 2024 in Vaccine
Verified
Journal Article
Closed access
MFMeredith B. Finn
Meredith B. Finn
TPThomas A. Penfound
Thomas A. Penfound
SSSanaz Salehi
Sanaz Salehi
COClinton O. Ogega
Clinton O. Ogega
CDChristina Dold
Christina Dold
JDJames Dale
James Dale

3 January 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
CDCailin Deal
Cailin Deal
ARAngelene F. Richards
Angelene F. Richards
TYTracy Yeung
Tracy Yeung
MMMax J. Maron
Max J. Maron
ZWZiqiu Wang
Ziqiu Wang
OPObadiah J. Plante
Obadiah J. Plante
Monoclonal antibody (mAb) therapy is a promising infectious disease intervention strategy but is limited to IgG1 isotypes that have restricted access to mucosal sites. IgA is well-established as the predominant antibody isotype in mucosal secretions but is clinically underutilized. To enable development of IgA-based mAbs, we exploited mRNA platform technology and demonstrated expression of functional, antigen-specific IgA (IgA mRNA ) that can limit bacterial invasion in the intestine and prevent colonization in the lung. Moreover, in vivo IgA mRNA had enhanced serum half-life and a greater degree of sialylation than a recombinantly produced IgA. The results underscore the potential of mRNA-based platforms to deliver protective human mAbs to mucosal surfaces and open new avenues to combat infectious diseases in the face of pervasive antibiotic resistance. One Sentence Summary: mRNA-encoded human monoclonal IgA traffics to mucosal tissues and provides protection against bacterial challenge